ERIS — Eris Lifesciences Income Statement
0.000.00%
Last trade - 00:00
- IN₹115.28bn
- IN₹121.84bn
- IN₹16.85bn
- 89
- 19
- 54
- 55
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9,822 | 10,741 | 12,119 | 13,470 | 16,851 |
Cost of Revenue | |||||
Gross Profit | 8,219 | 8,890 | 9,649 | 10,807 | 13,192 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 6,733 | 7,522 | 8,243 | 9,225 | 12,635 |
Operating Profit | 3,089 | 3,219 | 3,876 | 4,245 | 4,217 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 3,174 | 3,314 | 3,945 | 4,422 | 4,046 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2,911 | 2,965 | 3,551 | 4,058 | 3,742 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 2,908 | 2,965 | 3,551 | 4,061 | 3,822 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 2,908 | 2,965 | 3,551 | 4,061 | 3,822 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 21.2 | 21.8 | 26.1 | 30.2 | 28.2 |
Dividends per Share |